KTTA 4.39 Pasithea Therapeutics Corp.
| Range: | 3.61-17.4 | Vol Avg: | 933198 | Last Div: | 0 | Changes: | 0.33 |
| Beta: | 0.77 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Sep 15 2021 | Empoloyees: | 8 | ||
| CUSIP: | 70261F103 | CIK: | 0001841330 | ISIN: | US70261F2020 | Country: | US |
| CEO: | Dr. Tiago Reis Marques M.D., Ph.D. | Website: | https://www.pasithea.com | ||||
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow